

1/11




FIG. 1




FIG. 2

2/11




FIG. 3




FIG. 4

3/11




FIG. 5

4/11





FIG. 6

5/11



CTG-2227
Characteristics:
• R/R AML, M4 (myelomonocytic)
• Mutations: IDH1, FLT3 ITD, DNMT3A, NPM1, ASXL1
• Animals received 2 doses; Takedown and assessment at Day 41 post-implant

FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 9

Caspase induction was measured at 48 hr with the Caspase-Glo assay
GI90_100nM indicates 90% growth inhibition at 100nM dose
CTCL: Cutaneous T cell lymphoma
ALL: Acute lymphocytic leukemia
CML: Chronic myelogenous leukemia
ALCL: Anaplastic large cell lymphoma




FIG. 10




FIG. 11